BR112021011860A2 - Conjugados - Google Patents
Conjugados Download PDFInfo
- Publication number
- BR112021011860A2 BR112021011860A2 BR112021011860-8A BR112021011860A BR112021011860A2 BR 112021011860 A2 BR112021011860 A2 BR 112021011860A2 BR 112021011860 A BR112021011860 A BR 112021011860A BR 112021011860 A2 BR112021011860 A2 BR 112021011860A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- alkyl
- hydrogen
- group
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820626.8 | 2018-12-18 | ||
| GBGB1820626.8A GB201820626D0 (en) | 2018-12-18 | 2018-12-18 | Conjugates |
| PCT/EP2019/086120 WO2020127602A1 (en) | 2018-12-18 | 2019-12-18 | Conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021011860A2 true BR112021011860A2 (pt) | 2021-09-08 |
Family
ID=65147114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021011860-8A BR112021011860A2 (pt) | 2018-12-18 | 2019-12-18 | Conjugados |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220054658A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3897737A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022514335A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210106496A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113474007A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019400788A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021011860A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3123960A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201820626D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021006802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020127602A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685430B (zh) * | 2022-03-18 | 2023-07-21 | 浙江大学 | 芬苯达唑类似物及制备方法和应用 |
| WO2024049306A1 (en) * | 2022-08-31 | 2024-03-07 | Lopez Gonzalez Ricardo | Chemical conjugates, compositions, and methods of preparation and use thereof |
| CN120987848B (zh) * | 2025-07-10 | 2026-07-21 | 广州大学 | 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068485B1 (en) | 1981-07-01 | 1987-11-11 | Sanraku Incorporated | Novel antibiotics and process for production thereof |
| EP2370411A4 (en) * | 2008-12-05 | 2012-10-24 | Univ Oregon Health & Science | COMPOUNDS WITH ANTIPARASITIC OR ANTI-INFECTIOUS EFFECT |
| JP5852658B2 (ja) * | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| US20130345270A1 (en) * | 2010-11-12 | 2013-12-26 | Waake Forest University Health Sciences | Methods of treating cancer and other disorders |
| EP2665738B1 (en) | 2011-01-18 | 2018-09-26 | The Royal Institution for the Advancement of Learning/McGill University | Aminoglycosides for use in the treatment of bacterial infection |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| ES2907461T3 (es) * | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| WO2019060634A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
-
2018
- 2018-12-18 GB GBGB1820626.8A patent/GB201820626D0/en not_active Ceased
-
2019
- 2019-12-18 KR KR1020217022384A patent/KR20210106496A/ko not_active Ceased
- 2019-12-18 AU AU2019400788A patent/AU2019400788A1/en not_active Abandoned
- 2019-12-18 US US17/416,284 patent/US20220054658A1/en not_active Abandoned
- 2019-12-18 WO PCT/EP2019/086120 patent/WO2020127602A1/en not_active Ceased
- 2019-12-18 BR BR112021011860-8A patent/BR112021011860A2/pt unknown
- 2019-12-18 CA CA3123960A patent/CA3123960A1/en active Pending
- 2019-12-18 EP EP19829152.8A patent/EP3897737A1/en not_active Withdrawn
- 2019-12-18 JP JP2021535300A patent/JP2022514335A/ja active Pending
- 2019-12-18 CN CN201980092600.6A patent/CN113474007A/zh active Pending
- 2019-12-18 MX MX2021006802A patent/MX2021006802A/es unknown
-
2025
- 2025-01-17 JP JP2025007027A patent/JP2025072404A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201820626D0 (en) | 2019-01-30 |
| KR20210106496A (ko) | 2021-08-30 |
| JP2025072404A (ja) | 2025-05-09 |
| JP2022514335A (ja) | 2022-02-10 |
| US20220054658A1 (en) | 2022-02-24 |
| WO2020127602A1 (en) | 2020-06-25 |
| EP3897737A1 (en) | 2021-10-27 |
| CA3123960A1 (en) | 2020-06-25 |
| MX2021006802A (es) | 2021-08-16 |
| AU2019400788A1 (en) | 2021-08-12 |
| CN113474007A (zh) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6936498B2 (ja) | 抗アポトーシス性Bcl−2ファミリータンパク質の分解を誘導する化合物及びその使用 | |
| JP2025072404A (ja) | コンジュゲート | |
| JP2020143086A (ja) | アミロイド標的剤及びその使用方法 | |
| JP2020527559A (ja) | タウタンパク質分解の化合物 | |
| JP2022520518A (ja) | パンテテイン誘導体及びその使用 | |
| JP6952825B2 (ja) | 置換n−アセチル−l−システイン誘導体及び関連化合物 | |
| CN109071423A (zh) | 吲哚胺-2,3-双加氧酶(ido)抑制剂 | |
| TW202315863A (zh) | 脫磷酸裸蓋菇素之前藥及衍生物及其用途 | |
| JP2009051854A (ja) | チオールを含むnaaladアーゼ抑制物質 | |
| US12630498B2 (en) | Arylamides and methods of use thereof | |
| JP7564528B2 (ja) | 狂犬病の治療のための化合物およびその方法 | |
| JP4346239B2 (ja) | ビタミンe誘導体 | |
| JP7019585B2 (ja) | 核酸プロドラッグ | |
| US20230159439A1 (en) | Arylamides and methods of use thereof | |
| EA013244B1 (ru) | 8-МЕТОКСИ-9Н-ИЗОТИАЗОЛО[5,4-b]ХИНОЛИН-3,4-ДИОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОТИВОИНФЕКЦИОННЫХ СРЕДСТВ | |
| ES2992410T3 (es) | Inhibidores cetónicos de la lisina gingipaína | |
| CN115427396A (zh) | 用于预防或治疗脂质代谢相关疾病的化合物 | |
| JP7696301B2 (ja) | タンパク質分解のための化合物、組成物、および方法 | |
| CN106977506A (zh) | 二氢黄酮衍生物、其制备方法和用途 | |
| WO2022092294A1 (ja) | サルコペニア関連疾患等の新規治療および予防 | |
| KR20240145010A (ko) | Klf2 유도제 및 이의 사용 방법 | |
| CN112218878A (zh) | Ntcp抑制剂 | |
| US20250090548A1 (en) | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders | |
| CN121843700A (zh) | 用于治疗癌症的改性硫链丝菌素激发化合物以及其制备 | |
| CN113559102B (zh) | 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |